Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering Terje R. Pedersen, MD, Lars Wilhelmsen, MD, Ole Færgeman, MD, Timo E. Strandberg, MD, Gudmundur Thorgeirsson, MD, Linda Troedsson, Johan Kristianson, Kåre Berg, MD, Thomas J. Cook, MS, Torben Haghfelt, MD, John Kjekshus, MD, Tatu Miettinen, MD, Anders G. Olsson, MD, Kalevi Pyörälä, MD, Hans Wedel, PhD American Journal of Cardiology Volume 86, Issue 3, Pages 257-262 (August 2000) DOI: 10.1016/S0002-9149(00)00910-3
Figure 1 Profile of 4S. American Journal of Cardiology 2000 86, 257-262DOI: (10.1016/S0002-9149(00)00910-3)
Figure 2 Kaplan-Meier curves for all-cause mortality. American Journal of Cardiology 2000 86, 257-262DOI: (10.1016/S0002-9149(00)00910-3)
Figure 3 Kaplan-Meier curves for cancer mortality. American Journal of Cardiology 2000 86, 257-262DOI: (10.1016/S0002-9149(00)00910-3)
Figure 4 Kaplan-Meier curves for mortality in patients aged ≥65 years at baseline. American Journal of Cardiology 2000 86, 257-262DOI: (10.1016/S0002-9149(00)00910-3)
Figure 5 Kaplan-Meier curves for mortality in patients with LDL cholesterol <4.5 mmol/L at baseline. American Journal of Cardiology 2000 86, 257-262DOI: (10.1016/S0002-9149(00)00910-3)